NasdaqCM - Delayed Quote ? USD Elutia Inc. (ELUT) Follow Compare 3.8100 -0.0300 (-0.78%) At close: 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro?, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced the publication of preclinical data demonstrating that EluPro, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA), clears bacterial contamination associa GlobeNewswire ? 28 days ago ELUT -0.78% Elutia Celebrates First Year Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible. On September 6, 2023, as part of a strategic shift toward drug-eluting biologics, the company rebranded as Elutia Inc. and established the mission of “Humanizing Medicine so Patients can Thri GlobeNewswire ? last month ELUT -0.78% Elutia Announces First Patient Implant of EluPro?, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro?, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clini GlobeNewswire ? last month ELUT -0.78% Elutia to Participate in Upcoming Investor Conferences SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: H.C. Wainwright 26th Annual Global Investment ConferenceFormat: Presentation and 1x1 MeetingsPresentation Date and Time (On-demand beginning): Monday, September 9 GlobeNewswire ? last month ELUT -0.78% Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa GlobeNewswire ? last month BIDCF PCYO SIGY Elutia Announces Second Quarter 2024 Results Launch Production of EluPro? Underway, Commercial Team Expansion Continues, Financial Position SolidifiedSILVER SPRING, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the second quarter ended June 30, 2024. Business Highlights: Received FDA clearance for EluPro?, the first antibiotic-eluting BioEnvelope for protecting patients with implantable e GlobeNewswire ? 2 months ago ELUT -0.78% Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds SILVER SPRING, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced that it had received gross proceeds of approximately $15.7 million from the exercise of outstanding warrants to purchase common stock issued in a private placement financing completed in September 2023. “The cash proceeds from these warrant exercises significantly strengthen Elutia’s balance sheet and provide us with a solid f GlobeNewswire ? 2 months ago ELUT -0.78% Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. “We are pleased to welcome Ryan to the Elutia CRU as our new Vice Pres GlobeNewswire ? 2 months ago ELUT -0.78% Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 SILVER SPRING, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced that it will release its second quarter 2024 financial results after market close on Wednesday, August 7, 2024. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following in GlobeNewswire ? 2 months ago ELUT -0.78% SWK Holdings Highlights Recent Achievements and Provides Portfolio Update DALLAS, TX / ACCESSWIRE / July 17, 2024 /SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress ... ACCESSWIRE ? 2 months ago BIOL SWKH AOTI.L Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companie GlobeNewswire ? 2 months ago CVKD +5.86% GDTC CRVO Elutia to Present at the Emerging Growth Conference on Thursday, July 18 SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the Emerging Growth Conference on Thursday, July 18, 2024, at 12:35 p.m. ET (9:35 a.m. PT). Presentation Date: Thursday, July 18, 2024Presentation Time: 12:35 p.m. ET (9:35 a.m. PT)Webcast: Click here Following the presentation, Elutia management will also participate GlobeNewswire ? 3 months ago ELUT -0.78% Individual investors in Elutia Inc. (NASDAQ:ELUT) are its biggest bettors, and their bets paid off as stock gained 16% last week Key Insights The considerable ownership by individual investors in Elutia indicates that they collectively have a... Simply Wall St. ? 3 months ago ELUT -0.78% Elutia Announces $13.26 Million Registered Direct Offering SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The pre GlobeNewswire ? 3 months ago ELUT -0.78% Elutia Announces FDA Clearance of EluPro?: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for indications beyond CIEDs, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced th GlobeNewswire ? 3 months ago ELUT -0.78% Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024 SILVER SPRING, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, is excited to announce its participation in the upcoming Heart Rhythm Society's annual meeting (HRS 2024), where it will showcase its innovative CanGaroo? BioEnvelope product line. Designed specifically for cardiac implantable electronic devices (CIEDs), the biologic matrix of the envelope works with the body to promote a natural healing response and e GlobeNewswire ? 5 months ago ELUT -0.78% Elutia Announces First Quarter 2024 Results: SimpliDerm? Sales Increase 55%, CanGaroo?RM on Track for Second Quarter 2024 FDA Clearance SILVER SPRING, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the first quarter ended March 31, 2024. Business Highlights: Generated strong revenue growth for proprietary product lines in the first quarter of 2024, led by SimpliDerm net sales increasing 55% compared to the first quarter of 2023FDA interactions regarding CanGarooRM, Elutia GlobeNewswire ? 5 months ago ELUT -0.78% Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webc GlobeNewswire ? 5 months ago ELUT -0.78% Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las ... ACCESSWIRE ? 5 months ago MAMA ELUT -0.78% BIOYF Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1 SILVER SPRING, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024, at 3:00 p.m. ET (12:00 p.m. PT). Planet MicroCap Showcase: VEGAS 2024Presentation Date: Wednesday, May 1, 2024Presentation Time: 3:00 p.m. ET (12:0 GlobeNewswire ? 5 months ago ELUT -0.78% Performance Overview Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ELUT S&P 500 YTD +76.39% +22.49% 1-Year +168.31% +35.00% 3-Year -30.09% +30.66%
